Who founded NRG Therapeutics?

NRG Therapeutics was founded by Neil Miller, Richard Rutter.

Who are NRG Therapeutics's investors?

NRG Therapeutics's investors include Criteria Bio Ventures, Novartis Venture Fund, SV Health Investors, British Business Bank, M Ventures, Dementia Discovery Fund, Omega Funds.

How much funding has NRG Therapeutics raised?

NRG Therapeutics has disclosed $67M raised across 1 of its 2 known rounds.

NRG Therapeutics

24 employees on LinkedIn · 12 known investors

Find your way into NRG Therapeutics

802 people in our graph share verified history with the NRG Therapeutics team — schools, employers, funds. One of them is your warm intro.

Mathias Frederiksenunlockedknows Claus Sundgreen · together at NRG Therapeutics (overlapped)

×5knows the team · via NRG Therapeutics

×4knows the team · via Karolinska Institutet

×2knows the team · via GlaxoSmithKline

NRG Therapeutics is a biotech company developing small-molecule drugs targeting the mitochondrial permeability transition pore (mPTP) for neurodegenerative diseases such as ALS and Parkinson's. Its team combines pharma and biotech drug discovery expertise across neurology and neuroscience.

Biotech Healthtech Longevity

Founders & leadership

Neil MillerCEO

Richard Rutter CSORichard Rutter has over 20 years of drug discovery experience in preclinical pharmacology and biology, including previous roles as Chief Scientific Officer at Auspherix, an anti-infectives biotech. He is Chief Scientific Officer at NRG Therapeutics.

Grant HawthorneCOO

Claus Sundgreen Chief Medical OfficerClaus Sundgreen is Chief Medical Officer at NRG Therapeutics with over 25 years of experience in clinical development for neurodegenerative diseases, including ALS and orphan indications, spanning preclinical through registrational stages. He has held CMO and senior medical leadership roles focused on clinical strategy, regulatory engagement, and global program execution.

Paul Thompson CDOChief Development Officer at NRG Therapeutics, a biotech company developing small-molecule drugs for neurodegenerative diseases. Thompson has held executive-level R&D leadership roles focused on translational drug discovery and has experience in securing private investment and forming business partnerships.

Board

Jonathan SavidgeIndependent Non Executive Chair

Investors · 12

Criteria Bio Ventures✓ confirmed by NRG TherapeuticsBarcelona

How we know: the company's own site · businesscloud.co.uk · Not right? Tell us

Novartis Venture Fund✓ confirmed by NRG TherapeuticsBasel · $5M – $25M

How we know: Novartis Venture Fund's portfolio page · the company's own site · a partner's Signal profile · businesscloud.co.uk · Not right? Tell us

SV Health Investors✓ confirmed by NRG TherapeuticsLondon · $1M – $20M

How we know: SV Health Investors's portfolio page · the company's own site · funding news · Not right? Tell us

British Business Bank✓ confirmed by NRG TherapeuticsSheffield

How we know: the company's own site · businesscloud.co.uk · Not right? Tell us

M Ventureslisted by M VenturesLos Angeles · $10.8M

How we know: businesscloud.co.uk · the VCSheet dataset · Not right? Tell us

Dementia Discovery FundreportedLondon

How we know: funding news · cen.acs.org · Not right? Tell us

Omega FundsreportedBoston

How we know: businesscloud.co.uk · Not right? Tell us

Also in the syndicate · 5

Merck KGaANovartisParkinson's UKSV Health Investors' Dementia Discovery FundleadSV Health Investors' Dementia Discovery Fund (DDF)lead

Funding

SEC filings, press & company announcements

$67M disclosed across 1 of 2 rounds · 2022–2025

$67Mseries BSep 2025 · 4 sources
Dementia Discovery Fund (lead), SV Health Investors' Dementia Discovery Fund (lead), SV Health Investors' Dementia Discovery Fund (DDF) (lead), Brandon Capital, British Business Bank, Criteria Bio Ventures, M Ventures, Merck KGaA, Novartis, Novartis Venture Fund, Omega Funds, Parkinson's UK
Source ↗
Undisclosed amountSeries ANov 2022
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Frequently asked questions

What does NRG Therapeutics do?: NRG Therapeutics is a biotech company developing small-molecule drugs targeting the mitochondrial permeability transition pore (mPTP) for neurodegenerative diseases such as ALS and Parkinson's. Its team combines pharma and biotech drug discovery expertise across neurology and neuroscience.
Who founded NRG Therapeutics?: NRG Therapeutics was founded by Neil Miller, Richard Rutter.
Who are NRG Therapeutics's investors?: NRG Therapeutics's investors include Criteria Bio Ventures, Novartis Venture Fund, SV Health Investors, British Business Bank, M Ventures, Dementia Discovery Fund, Omega Funds.
How much funding has NRG Therapeutics raised?: NRG Therapeutics has disclosed $67M raised across 1 of its 2 known rounds.